Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from Patients with Ovarian Carcinoma

A. HARLOZIŇSKA, P. SEDLACZEK, J. KULPA, M. GRYBOS, E. WOJCIK, A. VAN DALEN and R. EINARSSON
Anticancer Research March 2004, 24 (2C) 1149-1158;
A. HARLOZIŇSKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. SEDLACZEK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. KULPA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. GRYBOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. WOJCIK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. VAN DALEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. EINARSSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

VEGF is an important angiogenic cytokine with a critical role in tumor angiogenesis. VEGF concentrations were measured using an ELISA assay, detecting VEGF165 isoform, in tumor cyst and/or ascitic fluids and in sera of 86 patients with malignant neoplasms and in 53 patients with benign ovarian neoplasms. VEGF levels were significantly elevated in the sera and cyst fluids of carcinoma patients compared with patients who had benign neoplasms. In carcinoma patients, statistically higher VEGF levels were detected in tumor effusions than in corresponding sera. The differences between VEGF values in sera and tumor effusions in relation to histological subtypes of ovarian carcinoma and FIGO stages were statistically insignificant. High VEGF levels in ascitic fluids appeared to be significantly associated with shorter disease-free survival and overall survival. In multivariate analysis, besides FIGO stage and age of patients, only serum VEGF concentration was an independent prognostic factor for overall survival. The elevated VEGF levels in sera and tumor effusions of patients with FIGO stages I/II indicated that angiogenesis promoted by VEGF is a continuous process, independent of clinical advancement of the disease.

Footnotes

    • Received November 5, 2003.
    • Accepted February 25, 2004.
  • Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 24 (2C)
Anticancer Research
Vol. 24, Issue 2C
March-April 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from Patients with Ovarian Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
15 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from Patients with Ovarian Carcinoma
A. HARLOZIŇSKA, P. SEDLACZEK, J. KULPA, M. GRYBOS, E. WOJCIK, A. VAN DALEN, R. EINARSSON
Anticancer Research Mar 2004, 24 (2C) 1149-1158;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from Patients with Ovarian Carcinoma
A. HARLOZIŇSKA, P. SEDLACZEK, J. KULPA, M. GRYBOS, E. WOJCIK, A. VAN DALEN, R. EINARSSON
Anticancer Research Mar 2004, 24 (2C) 1149-1158;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
  • Google Scholar

More in this TOC Section

  • Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis
  • Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy
  • Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire